unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial) [J]. Thorac Cancer. 2022 Dec;13(23):3431-3435. doi: 10.1111
624 Tumor biomarkers in lung cancer: An analysis of patients with pathologically staged N1 nonsmall cell lung cancer (NSCLC)A five year survival rate of the pathologically staged patients ranges from 30% to 50%.Adjuvant treatment to improve this outcome is controversial, since which patients need...
[3]DyerM, GreenM, Joness, et al. Estimating long-term survival of previously untreated patients with EGFR mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC) who received osimertinib in the FLAURA stud...
[3]DyerM, GreenM, Joness, et al. Estimating long-term survival of previously untreated patients with EGFR mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC) who received osimertinib in the FLAURA study[J]. J Clin Oncol, 2019, 37(15Suppl): e20560-e20560. DOI: 10.120...
肺癌是国内发病率最高和死亡率最高的癌症之一,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)约占所有肺癌的85%。较传统的化疗方案,靶向治疗和免疫治疗极大地提高了晚期NSCLC患者的生存率,5年总生存(overall survival,OS)率达到了20%~30%[1-4]。在晚期的NSCLC取得成功后,靶向治疗和免疫治疗进一步拓展到早...
The combination of immune checkpoint inhibitors (ICIs) with chemotherapy (chemoimmunotherapy) in the neoadjuvant setting have achieved favorable clinical benefits in non-small cell lung cancer (NSCLC), but the mechanism of clinical responses remain uncle
survival as well as overall survival in xenograft models of EGFR-mutant NSCLC cells9. Further, acquisition of stemness phenotype after the emergence of EGFR-TKI resistance enhanced tumor metastasis in lung cancer10. Consequently, during a long-term exposure to TKIs, the appearance and enrichment ...
肺癌相关的血清肿瘤标志物包括癌胚抗原、糖类抗原(carbohydrate antigen, CA)125、CA153、细胞角蛋白片段19和鳞状上皮细胞癌抗原等,小细胞肺癌(small cell lung cancer, SCLC)具有神经内分泌特点,与促胃泌素释放肽前体、神经元特异性烯醇化酶、肌酸激酶BB以及嗜铬蛋白A(CgA)等相关,可作为监测治疗反应和早期复发的辅助...
Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Durvalumab after Chemoradiotherapy: PACIFIC-KR (J Thorac Oncol; IF:20.121) Corresponding Author: In-Jae Oh, MD, PhD. Department of Internal Medicine, Chonnam National University Medical School...
EGFR阳性的晚期NSCLC患者是否进入“Chemotherapy free”的时代?日本的Isamu Okamoto教授团队纳入了迄今为止样本量最大的EGFR突变阳性病人,分析了真实事件中影响 CGFR突变阳性晚期NSCLC患者的长期生存的因素,研究结果近期发表在Lung Cancer杂志上。来自同济大学附属肺科医院的任胜祥教授为您深度解读这一研究。